Format

Send to

Choose Destination
Radiother Oncol. 2010 Jul;96(1):19-24. doi: 10.1016/j.radonc.2010.04.018. Epub 2010 May 7.

The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer.

Author information

1
Laboratory of Radiobiology & Experimental Radiooncology, University Medical Center Hamburg-Eppendorf, Germany.

Abstract

PURPOSE:

Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors.

MATERIALS AND METHODS:

The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay.

RESULTS:

No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p=0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p=1.75(-9)). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%.

CONCLUSION:

G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.

PMID:
20452694
DOI:
10.1016/j.radonc.2010.04.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center